Literature DB >> 9421393

Activation of the signal transducers and activators of transcription signaling pathway by growth hormone (GH) in skin fibroblasts from normal and GH binding protein-positive Laron Syndrome children.

J S Freeth1, C M Silva, A J Whatmore, P E Clayton.   

Abstract

We have previously described two families (H and M) with GH binding protein-positive Laron Syndrome (LS), proposed to have one or more post GHR signaling defects. In the present study, we have examined whether the signal transducers and activators of transcription (STAT) pathway is activated by GH in skin fibroblast cultures established from these LS children, to determine the level(s) at which GH insensitivity has occurred. On immunoblots, both normal and LS fibroblasts express JAK2 and STATs 1, 3, and 5. GH induced rapid tyrosine phosphorylation of a protein at approximately 93 kDa in normal fibroblasts, and Western blotting with STAT-specific antibodies revealed STAT5 activation (phosphorylation) by GH. To determine further the identity and the DNA binding characteristics of the STAT proteins that were activated by GH, EMSAs were performed using three DNA elements known to bind STAT proteins; m67, the high affinity c-sis-inducible element (SIE), the interferon response element (IRE), and the lactogenic hormone-responsive region (LHRR). GH failed to induce protein binding to the SIE or IRE in normal skin fibroblasts but did induce the formation of a specific complex with the LHRR. Induction by GH of this LHRR/protein complex, which could be supershifted partially by anti-STAT1 antisera and completely by anti-STAT5 antisera, was transient, maximal between 10 and 30 min and reduced by 60 min. GH also induced distinct LHRR/protein complexes in mouse 3T3-F442A fibroblasts and in human IM-9 lymphocytes, but supershift analysis revealed that these complexes contained STAT5 but not STAT1. Whereas no binding to the LHRR was observed in GH-treated H fibroblasts, GH induced binding to this element in M fibroblasts. These results demonstrate that 1) the JAK-STAT pathway is activated by GH in normal fibroblasts and that STATs 1 and 5 have a role in GH-dependent signaling in these cells; 2) GH activation of DNA/STAT binding is cell type- and species-specific; and 3) GH failed to activate the STAT pathway in H fibroblasts but induced STAT signaling in M fibroblasts, indicating that the site of GH resistance in the latter is likely to be located within another GH signaling pathway. These fibroblast cultures therefore provide unique models with which to further our understanding of the mechanisms of human GH signaling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9421393     DOI: 10.1210/endo.139.1.5690

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

Review 1.  Identification of the first patient with a confirmed mutation of the JAK-STAT system.

Authors:  Ron G Rosenfeld; Eric Kofoed; Caroline Buckway; Brian Little; Katie A Woods; Junko Tsubaki; Katherine A Pratt; Liliana Bezrodnik; Hector Jasper; Alejandro Tepper; Juan J Heinrich; Vivian Hwa
Journal:  Pediatr Nephrol       Date:  2005-02-02       Impact factor: 3.714

Review 2.  STAT5 signaling in sexually dimorphic gene expression and growth patterns.

Authors:  H W Davey; R J Wilkins; D J Waxman
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

3.  Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments.

Authors:  Paolo P Provenzano; Adriana L Alejandro-Osorio; Kelley W Grorud; Daniel A Martinez; Arthur C Vailas; Richard E Grindeland; Ray Vanderby
Journal:  BMC Physiol       Date:  2007-03-26

4.  Metabolites involved in glycolysis and amino acid metabolism are altered in short children born small for gestational age.

Authors:  Philip G Murray; Imogen Butcher; Warwick B Dunn; Adam Stevens; Reena Perchard; Daniel Hanson; Andrew Whatmore; Melissa Westwood; Peter E Clayton
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.